Stock Ratings / Health Care / GALT / earnings

SPRY (20) AVIR (33) EBS (48) CYPH (42) ⌘ Pro Terminal →

Galectin Therapeutics Inc. (GALT) Next Earnings Date & Expected ±12.5% Move

$3.32 -5.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.28

Galectin Therapeutics Inc. (GALT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $335.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GALT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Galectin Therapeutics Inc. (NASDAQ: GALT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.32 (-5.68% 1D, market cap $335.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GALT ranks #536 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GALT compare to SPRY and AVIR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GALT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $336.1M) and AVIR (Atea Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $329.6M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GALT?

▼

Per GALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001133416), Galectin Therapeutics Inc. generated $0 in revenue, -$30.8M in net income, and -$23.9M in free cash flow against $19.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.28 (-1.21%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GALT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY GALT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.69-7% Next Q

Q2 (-2Q)

Grade D$3.43-1.5% Next Q

Q3 (-1Q)

Grade D$3.38-1.8% Next Q

Current

Grade D-$3.32-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GALT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GALT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.80) and Max Pain ($3.49) forces dealer call-delta covering toward $7.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GALT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GALT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.41 Expected Swing

MODEL EARNINGS SETUP GAUGE

GALT Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$30.8M	-$23.9M	52%
FY 2024	2024-12-31	$0	-$47.0M	-$41.8M	52%
FY 2023	2023-12-31	$0	-$41.1M	-$33.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GALT)

✓Walkthrough of GALT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GALT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +44.98%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.52H $3.52L $3.32C $3.32VOL 174.8K

RES: $3.82SUP: $3.15SMA50: $3.80SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GALT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GALT Butterfly Map → + Track GALT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GALT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GALT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GALT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GALT)

Health Care Rank #536 of 1016 ⚔️ SPRY vs GALT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GALT vs. SPRY, AVIR, EBS, CYPH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Galectin Therapeutics Inc. (GALT) ranks #536 by composite RQD confidence (37/100, grade D-) and #503 by equity capitalization ($335.6M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with GALT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GALT ACTIVE Galectin Therapeutics Inc.	D-	37/100	—	—	-35.0%	-5.68%	$335.6M	Benchmark Subject
SPRY ARS Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-7.65%	$336.1M	/spry-vs-galt →
AVIR Atea Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-4.64%	$329.6M	/avir-vs-galt →
EBS Emergent BioSolutions Inc.	D	48/100	7.0x	56.1%	8.9%	-5.68%	$349.2M	/ebs-vs-galt →
CYPH Cypherpunk Technologies Inc.	D-	42/100	71.3x	—	-23.3%	-9.97%	$321.1M	/cyph-vs-galt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001133416

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Galectin Therapeutics Inc. (GALT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$30.8M, operating cash flow of -$23.9M, and free cash flow of -$23.9M (+42.8% YoY). On the balance sheet, GALT closed FY2025 with $19.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$30.8M	-$23.9M	-$23.9M	$19.5M	—
FY2024 (FY)	2024-12-31	$0	-$47.0M	-$41.8M	-$41.8M	$17.5M	—
FY2023 (FY)	2023-12-31	$0	-$41.1M	-$33.0M	-$33.0M	—	—

3. GALT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GALT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GALT compare to SPRY and AVIR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GALT?

Where is GALT trading relative to its 50-day, 200-day, and 52-week technical levels?

GALT last traded at $3.32 (-5.68% on volume of 174,752 shares), positioning the stock -12.63% below its 50-day simple moving average ($3.80) and +3.43% above its 200-day simple moving average ($3.21). Across its 52-week range of $2.03 to $7.13, GALT sits at the 25.3% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.91 to $3.73).

GALT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GALT's next earnings date?

Based on SEC filing cadence, Galectin Therapeutics Inc. (GALT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is GALT stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GALT, spanning a range between $2.91 and $3.73.

Direct Sub-Reports: GALT RQD Cockpit GALT 12M Forecast GALT Earnings & Move GALT Dividends & DRIP GALT Insiders & 13F GALT Whale Options GALT Profit Sankey GALT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GALT — Galectin Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:53Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GALT scores 39 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 8/20, reflecting an ROIC of -35% and an FCF yield of -6.71%. The whale 13F flow pillar scores 7/20, tied to institutional accumulation and options positioning. The insider conviction pillar scores 3/20, based on SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 11/20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10/20, citing an Altman Z of 2.5, a Piotroski F of 3/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating's weakest pillars are the operating cash engine and insider conviction, which together suggest the company is consuming cash and lacks visible insider endorsement. The forensic balance sheet score is middling rather than distressed, and the cited Altman Z of 2.5 and Debt/Equity of 0.5 indicate the company is not presently in the most acute financing stress per the rating's own inputs. Upside drivers implied by the source data are limited to the news-flow items described below, which the rating does not weight explicitly. Valuation tradeoffs are difficult to frame because P/E, EV/EBITDA, and EPS are not available in source data, so the stock cannot be benchmarked on earnings. This analysis is educational and is not personalized financial advice.

Business

Galectin Therapeutics Inc. is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it operates with a market capitalization of $0.4B. The source data does not describe its products, customers, or revenue model. Revenue is reported as $0.0M in each of the three listed fiscal years.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-20.1M	$-30.8M	N/A	$-23.9M	$17.7M	N/A
FY 2024	$0.0M	$-42.4M	$-47.0M	N/A	$-41.8M	$15.1M	N/A
FY 2023	$0.0M	$-38.1M	$-41.1M	N/A	$-33.0M	N/A	N/A

Per the SEC financials, the company reported operating losses in every listed period, and gross, operating, and net margins are each 0% in the market data. ROIC is -35% per the market data. The Roarable rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. Cash was $17.7M at FY 2025 versus $15.1M at FY 2024, and FY 2025 operating loss narrowed to $-20.1M from $-42.4M. Debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, the headlines include a SEC filing dated Oct 13, 2026 and a Seeking Alpha item framing a $105M debt conversion as clearing the balance sheet while a Phase 3 partnership is described as critical. Market wire items note the shares crossing above a 200-day moving average and a day's decline to $3.66 with call-dominated activity. The feed's light flags are mostly YELLOW, with one GREEN item tagged CATALYST, the Seeking Alpha debt-conversion piece. Risk watch items include the dependence on a Phase 3 partnership, as referenced in that headline. The Butterfly supply-chain graph reports no supply chain, no butterfly links, and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context is the Health Care classification and the beta of 1.0. A prospective investor should watch the Phase 3 partnership referenced in the news feed as the principal external dependency, though the source data does not identify its counterparty or timing.

Open Questions

What is the company's debt position, given that debt is not available in source data while a $105M debt conversion is referenced in the news feed?
What is the status and counterparty of the Phase 3 partnership described as critical?
What are the company's revenue sources, given revenue is $0.0M in all listed periods?
What is the current cash runway relative to the reported FY 2025 operating loss of $-20.1M and FCF of $-23.9M?
Why are EPS and valuation multiples unavailable, and how would they change the valuation assessment?

GALT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Galectin Therapeutics Inc. (GALT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GALT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 17h ago

Galectin Therapeutics Inc. (GALT) Seasonal Returns Chart

Yahoo! Finance Canada report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 20h ago

Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical

Seeking Alpha report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 23h ago

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why

MarketBeat report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

GALECTIN THERAPEUTICS INC SEC Filing (Oct 13, 2026)

Stock Titan report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why

MarketBeat report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Galectin Therapeutics (GALT) Slips 1.35% to $3.66 as Shares Sit Between Key Levels - Call Dominated

https://www.siam.in/ report covering Galectin Therapeutics Inc. (GALT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GALT Bull vs. Bear Conversation Board — What's Your Call at $3.32?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GALT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.10 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GALT (D- • RQD 39/100) a Buy at $3.52?

Welcome to the GALT (Galectin Therapeutics Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.68 (-23.9%)

Spot @ $3.52

Pump the brakes on GALT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GALT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Galectin Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.12 (+17.0%)

Spot @ $3.52

GALT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GALT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.52 (52-wk range $2.03 - $7.13), any beat on forward guidance forces shorts and underweight funds to chase.